Alyeska Investment Group
MCRB icon

Alyeska Investment Group’s Seres Therapeutics MCRB Stock Holding History

Alyeska Investment Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,298
Closed -$769K – 431
2015
Q3 		$769K Sell
1,298
-202
-13% -$165K 0.01% 405
2015
Q2 		$1.25M Buy
+1,500
New +$1.31M 0.01% 392

Other funds holding MCRB

FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Alyeska Investment Group's MCRB Position: Q4 2015 in Review

Alyeska Investment Group sold out of Seres Therapeutics (MCRB) in Q4 2015, closing a stake of 1,298 shares — an estimated $769K sold.

Alyeska Investment Group first reported a position in MCRB in Q2 2015 and held it in 2 quarters. The position peaked at $1.25M in Q2 2015. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2015.

  • Alyeska Investment Group reported no remaining Seres Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 1,298 Seres Therapeutics shares in Q4 2015, an estimated $769K.
  • Alyeska Investment Group first reported a position in Seres Therapeutics in Q2 2015 and held it in 2 quarters.
  • Alyeska Investment Group's Seres Therapeutics position peaked at $1.25M in Q2 2015.
  • 69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2015.

Based on Alyeska Investment Group's 13F filing for Q4 2015, filed 16 Feb 2016.